Abstract

Background and Aim: The new standard of care for patients with chronic hepatitis C genotype 1 (GT1) is triple therapy with pegylated interferon alpha (P), ribavirin (R) and a HCV protease inhibitor (PI). Sustained virological response (SVR) has been shown to lower the incidence of HCC, improve survival and even regression of liver cirrhosis is suggested in some cases. However, data are limited, especially for triple therapy. We aim to evaluate the impact of SVR after triple therapy including PIs on liver fibrosis by non-invasive fibrosis measures in a real-world setting.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.